Vensica Medical Receives FDA IND Clearance for Phase 2 Trial of Needle-Free Botulinum Toxin Delivery System for Overactive Bladder
Key Insights
Vensica Medical (search) received FDA IND clearance to initiate a Phase 2 clinical trial of ViXe, combining its Vibe ultrasound-based needle-free delivery system with Xeomin for overactive bladder (search) treatment.
The Phase 2 study will enroll approximately 210 patients across the United States and Europe to evaluate safety and efficacy of the needle-free botulinum toxin delivery approach.
Overactive bladder (search) affects an estimated 33 million adults in the United States, with current botulinum toxin treatments limited by invasive needle-based procedures.
Vensica Medical (search), a clinical-stage company developing needle-free therapeutic delivery solutions for urologic diseases, announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of ViXe. The study will evaluate the Vibe ultrasound-based, needle-free drug delivery system in combination with Xeomin (incobotulinumtoxinA) for the treatment of overactive bladder (search) (OAB).
Addressing a Significant Medical Need
Overactive bladder (search) affects an estimated 33 million adults in the United States and is characterized by urinary urgency, frequency, and incontinence. While intravesical botulinum toxin injection is an established second-line treatment, the invasive procedure limits patient access and acceptance. The ViXe program is designed to enable effective delivery of botulinum toxin into the bladder wall without the need for needles.
Phase 2 Trial Design and Timeline
The Phase 2 study is expected to enroll approximately 210 patients across sites in the United States and Europe and will evaluate the safety and efficacy of Vibe-enabled delivery of botulinum toxin type A. The company anticipates initiating patient enrollment in Q3 2026.
Leadership Commentary
"FDA clearance of this IND is an important milestone for Vensica and validates the clinical rationale behind the ViXe program," said Avner Geva, Chief Executive Officer of Vensica Medical (search). "Botulinum toxin is a proven therapy for OAB, but needle-based delivery remains a barrier for many patients. We believe ViXe has the potential to expand access to a much broader population."
Avi Eftel, Co-Founder and Chief Technology Officer of Vensica Medical (search), emphasized the technological innovation: "The Vibe platform was specifically engineered to overcome biological barriers that have historically limited needle-free delivery of large-molecule drugs. We look forward to executing this study and generating data to further demonstrate the clinical value of our approach."
Strategic and Financial Implications
Ken Berlin, Executive Chairman of the Board of Vensica Medical (search), highlighted the broader significance: "This IND clearance represents a key milestone in Vensica's development and highlights the potential of the ViXe program. A needle-free approach to botulinum toxin delivery could meaningfully expand patient access and create significant value for patients, partners, and investors."
The IND clearance triggers a contractual development milestone payment from Vensica's strategic partners, supporting execution of the Phase 2 trial. Vensica is supported by its investors and strategic partners, including Merz Pharma (search), Laborie (search), and Israel Biotech Fund (search).
Technology Platform
Vensica Medical (search)'s proprietary Vibe platform uses focused ultrasound to enable localized delivery of biologic and small-molecule drugs into the bladder wall. The company's lead program, ViXe, combines the Vibe system with Xeomin (incobotulinumtoxinA) for the treatment of overactive bladder (search).